Dec 22, 2008 - TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced that the U.S. FDA has granted Orphan Drug Designation for its anti-cancer compound 131I-TM601 for the treatment of Stage IIb-IV melanoma.
The whole story can be read here.
No comments:
Post a Comment